Companies in #Gastroenterology

Bausch Health Companies Inc. (NYSE: BHC) is a diversified specialty pharmaceutical and medical device company headquartered in Laval, Quebec, operating through five reporting segments: Salix (gastroenterology), International, Solta Medical (aesthetic devices), Diversified, and Bausch + Lomb. Its products span gastroenterology, hepatology, neurology, dermatology, dentistry, over-the-counter medicines, aesthetic devices and eye health, sold across the United States, Canada, Europe, China, Japan, Mexico and other markets. The company traces its lineage to ICN Pharmaceuticals, founded in 1960, which became Valeant Pharmaceuticals International and was renamed Bausch Health Companies in July 2018. Q3 2026 revenue was $2.90 billion with adjusted earnings per share of $1.77, and management raised full-year 2026 guidance to $5.525–5.625 billion of revenue and $3.225–3.275 billion of adjusted EBITDA. The equity carries roughly $18 billion of net debt against a market capitalisation near $3.3 billion, which makes balance-sheet actions — debt repurchase, refinancing and deleveraging — as important to the share price as quarterly earnings.

Cumberland Pharmaceuticals is a U.S. specialty pharmaceutical company focused on acquiring, developing, and commercializing prescription products for hospital acute-care and gastroenterology. Founded in Nashville in 1999, the company markets brands including Acetadote, Caldolor, Kristalose, and Vibativ. In 2026 it completed a $100 million strategic transaction with an affiliate of Apotex, the largest Canadian pharmaceutical company, in which Apotex acquired Cumberland's line of branded pharmaceuticals at closing (July 1, 2026), funded a special shareholder dividend, and sharpened Cumberland's focus on its late-stage orphan-drug pipeline, including ifetroban and a Duchenne muscular dystrophy candidate holding FDA orphan and rare pediatric disease designations.

Neurological drug and medical device company developing “on demand” therapies that restore bowel and bladder control for people with neurological disorders.

Swiss medtech company developing implantable medical devices for chronic conditions. Lead product RefluxStop is an FDA-approved and CE-marked implant for the treatment of gastroesophageal reflux disease (GERD).

Italian pharmaceutical company specializing in biologics, CDMO services, and specialty pharmaceuticals. Active in European and global markets with recent expansion into obesity therapeutics via GLP-1 licensing deals.

Nitinotes is a medical devices company. See today's news for the latest developments.